AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01817166 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Urine samples
Description: Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.
Study NCT01817166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urine samples
Description: Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.
Study NCT00494429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Gestational Age\< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.
Study NCT00494429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Gestational Age>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
Study NCT02044562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate supplementation
Description: A 70 ml beetroot juice containing 0.45g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
Study NCT02044562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 70 ml placebo containing 0 g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
Study NCT02448745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insecticide treated wall lining
Description: Polypropylene non-woven fabric.
Study NCT01995344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT02627443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV
Study NCT02627443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02627443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02627443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02627443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03793478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28
Study NCT03793478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)
Study NCT03793478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2000 mg/m\^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care);~Optional high intensity consolidation with chemotherapy and quizartinib:~500 mg/m\^2/day as a continuous 96-hour IV infusion on Days 1 through 4;~Optional low intensity consolidation with chemotherapy:~75 mg/m\^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18
Study NCT03793478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) triple chemotherapy prophylaxis
Description: IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site
Study NCT03793478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Optional high intensity consolidation with chemotherapy and quizartinib:~100 mg/m\^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5
Study NCT06068075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FoundationOne Liquid CDx
Description: a FoundationOne liquid biopsy test kit will be sent to the laboratory of the subject's treating center, in addition to the paired cell stabilizing tube from the primary center
Study NCT03394365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tabelecleucel
Description: Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
Study NCT04507555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacist-guided pharmacogenetic (PGx) testing for antidepressant selection and dosing
Description: The study intervention is the service of pharmacist guided pre-emptive PGx testing to support clinical decision making for antidepressant selection and dosing.~This service involves genotyping and thereof evidence-based genotype interpretation commercially offered as Stratipharm® (humatrix AG, Pfungstadt Germany, https://www.stratipharm.de). Furthermore, clinical pharmacists will process and evaluate the results from PGx testing (Stratipharm®) in context of the individual patient medication history as well as current co-medication and forward an individualized recommendation for antidepressant selection and dosing to the treating psychiatrist.
Study NCT04507555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care antidepressant selection and dosing
Description: Selection and dosing of the new antidepressant pharmacotherapy will be determined by the treating investigator alone, according to current standard of care considering clinical factors only.
Study NCT04396236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally
Study NCT04396236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT04396236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT04396574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally
Study NCT01995344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Study NCT01995344 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Tumour Infiltrating Lymphocytes
Study NCT01995344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Study NCT03026829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CART sound therapy
Description: The study consists of two parts:~Phase 1: laboratory evaluation of CART sound acceptability~Phase 2: take home evaluation of CART sound therapy including baseline without CART
Study NCT00078845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: 500 mg three times a week.
Study NCT03426943 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arterial blood sampling
Description: All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels
Study NCT03426943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arterial blood sampling
Description: All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels
Study NCT03426943 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ultrafiltrate sampling
Description: All patients will have ultrafiltrate sampling to assess cytokine levels
Study NCT03426943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ultrafiltrate sampling
Description: All patients will have ultrafiltrate sampling to assess cytokine levels
Study NCT03426943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVVH using oXiris™ filter
Description: Patients included in the experimental arm will have renal replacement therapy by performing CVVH using oXiris™ filter
Study NCT03426943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH using PrismafleX HF1400 filter
Description: Patients included in the experimental arm will have renal replacement therapy by performing CVVH using PrismafleX HF1400 filter
Study NCT04873635 — intervention group
Intervention type: OTHER
Intervention: Implant support prostheses
Description: Implant support prostheses was provided to restore the missing teeth and tissues removed due to pathological jaw lesions
Study NCT00996034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
Study NCT00996034 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [123I]5-IA-85380
Description: up to 10 mCi of \[123I\]5-IA-85380, I.V. on each of two SPECT Scan days
Study NCT00996034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine bitartrate
Description: 0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
Study NCT00647595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Intervention group will exercise 3 times per week at moderate-vigorous intensity for 45 minutes per session. Control group women will continue their usual physical activity throughout pregnancy.
Study NCT01602497 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC
Study NCT01602497 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS
Description: Patients will undergo ten session of sham rTMS.
Study NCT03833232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omentopexy with cyanoacrilate glue
Description: apposition of omentum with cyanoacrilate glue on gastric section
Study NCT03910881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open-platform patient support system (PSS) app
Description: The PSS app enables tracking and visualization of patient-selected health outcomes and sharing of select outcomes with family and providers. The CF clinical team and the family jointly decide which aspects of daily life to track, how often, and the content and frequency of patient-generated reports. Examples of daily care that can be tracked include symptoms (respiratory, gastrointestinal, pain), energy level, appetite, sleep, exercise, mood, medications, therapies, school/work attendance. Prior to a clinic visit, the patient/family generates a report of the outcomes they have been tracking, to help prepare for the visit and identify successes and areas of struggle. This information facilitates meaningful conversations during the visit and promotes shared decision-making. Patients/families can view their progress at any time and share selected outcomes with family and friends as often as desired.
Study NCT03683563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4% sodium citrate
Description: the catheter will be locked with 4% citrate solution after each dialysis session
Study NCT03683563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30% sodium citrate
Description: the catheter will be locked with 30% citrate solution after each dialysis session
Study NCT01502033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: 30 daily treatments of (over 6-8 weeks) of 10 Hz rTMS at 120% motor threshold, applied to the left dorsolateral prefrontal cortex with 3,000 stimulations per treatment
Study NCT02018432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast escalation dosage
Description: This is a randomized, prospective, open label, comparative study to assess whether the administration of roflumilast by dose escalation varies the incidence of discontinuations due to adverse events when compared with the usual dosage in severe and very severe COPD patients.~Roflumilast 250 μg once daily for 4 weeks and then increased dose of Roflumilast 500 μg once daily for 12 weeks
Study NCT02018432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast conventional dosage
Description: Roflumilast 500 μg once daily for 12 weeks
Study NCT01124799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days
Study NCT01124799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo dose in the morning, at noon and in the evening, for 9 days
Study NCT01124799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days
Study NCT04003376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fractional carbon dioxide laser alone
Description: six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions
Study NCT04003376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser alone
Description: six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions
Study NCT04003376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 10mg/mL
Description: six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide
Study NCT04003376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
Study NCT04003376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D solution
Description: six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
Study NCT02935296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Intervention
Description: systems navigation, psychosocial counseling
Study NCT01158937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Infusion
Description: Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)
Study NCT01592123 — intervention group
Intervention type: PROCEDURE
Intervention: The active anterior rhinomanometry
Description: In this method, the airflow through 1 nasal cavity and the pressure gradient across this nasal cavity are measured simultaneously at each breath as recommended by the committee report on the standardization of rhinomanometry. All measurements were performed under the same standard conditions. Herein, all presented airflow values are the sum of inspiratory airflow of the right and left sides of the nose at 150 pascals (Pa). And, total nasal airflow (cm3/s) and airway resistance (Pa/cm3/s) values were used for statistical analyses.
Study NCT01592123 — intervention group
Intervention type: BEHAVIORAL
Intervention: The Pittsburgh Sleep Quality Index (PSQI)
Description: PSQI was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers. The self-administered scale contains 15 multiple-choice items that inquire about frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range of 0-21). A PSQI global score >5 is considered to be suggestive of significant sleep disturbance.
Study NCT01592123 — intervention group
Intervention type: BEHAVIORAL
Intervention: The Beck Anxiety Inventory (BAI)
Description: The BAI is a 21-item self-report questionnaire that lists symptoms of anxiety. The respondent is asked to rate how much each symptom has bothered him/her in the past week. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (3). The instrument has excellent internal consistency and high test-retest reliability. The BAI has been widely used to measure severity of anxiety by self-report.
Study NCT01592123 — intervention group
Intervention type: BEHAVIORAL
Intervention: The Van Dream Anxiety Scale (VDAS)
Description: The VDAS provides the assessment of nightmare frequency and dream anxiety caused by frightening dreams during the preceding month. There are 17 self-rated questions in the scale. Twelve questions (1-4, 6, 11-17) that are tabulated in the scoring are weighted equally on a 0-4 scale. Question 5 is related to autonomic hyperactivity and consists of 12 symptoms. Each of 12 symptoms is also weighted on a 0-4 scale. Thirteen question scores are summed to yield a global VDAS score, which has a range of 0-42.
Study NCT00791037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given ID
Study NCT00791037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Undergo leukapheresis
Study NCT00791037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ex vivo-expanded HER2-specific T cells
Description: Given IV
Study NCT00791037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00791037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given ID
Study NCT00791037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT02999841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: 1-2 week: 50mg tid; 3-24 week: 100mg tid.
Study NCT02999841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: 1-24 week: 50mg bid
Study NCT02264210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
Study NCT03956030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contraception Handout
Description: Handout covering contraception options
Study NCT03956030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Handout
Description: Handout covering nutrition
Study NCT02298088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 180 mg
Description: Ticagrelor, 180 mg as early as possible after the index event and not >24 h post event followed by 90 mg twice daily for 12 months.
Study NCT02298088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300 mg clopidogrel as early as possible after the index event and not > 24h post event, followed by 75mg/day for 12 months.~For patients with > 75 years the recommended load dose is 75 mg instead 300 mg.
Study NCT02890563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Class II Compression Stockings
Study NCT00597389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inderol (propranolol)
Description: Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
Study NCT00597389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inderol (propranolol)
Description: Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
Study NCT03973398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum block
Description: ultrasound guided Quadratus Lumborum block for postoperative pain
Study NCT03973398 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus Lumborum block
Description: ultrasound guided Quadratus Lumborum block for postoperative pain
Study NCT03864523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study NCT04671394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMUD + DLIG
Description: Full-Mouth Ultrasonic Debridement + Diode Laser and Indocyanine Green solution
Study NCT04671394 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: FMUD + ST
Description: Full-Mouth Ultrasonic Debridement + Sham Treatment
Study NCT03727841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marizomib
Description: 0.8mg/m(2) intravenous (IV) on days 1, 8, and 15 of each 28-day cycle, 24 cycles total.
Study NCT01761929 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance
Description: All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
Study NCT00519584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30 ml 0.5%
Study NCT00519584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 30 ml 0.5%
Study NCT00519584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dex
Description: 8 mg (2 ml)
Study NCT00519584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 30 ml 0.5%
Study NCT00519584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30 ml 0.5%